Editorial

• Literatur

• 1 Donders FC. Beiträge zur pathologischen Anatomie des Auges; 2) Pigmentbildung in der Netzhaut. Graefes Arch Clin Exp Ophthalmol 1857; 3: 139-150
• 2 von Graefe A. Vereinzelte Beobachtungen und Bemerkungen. Exceptionelles Verhalten des Gesichtsfeldes bei Pigmententartung der Netzhaut. Arch Ophthalmol 1858; 4: 250-253
• 3 Bateson W. Mendelʼs Principles of Heredity – A Defence, with a Translation of Mendelʼs Original Papers on Hybridisation. Cambridge, UK: Cambridge University Press; 2009
• 4 Daiger SP. Identifying retinal disease genes: how far have we come, how far do we have to go?. Novartis Found Symp 2004; 255: 17-27 doi:10.1002/0470092645.ch3
• 5 Russell S, Bennett J, Wellman JA. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017; 390: 849-860 doi:10.1016/S0140-6736(17)31868-8
• 6 Cideciyan AV, Aleman TS, Boye SL. et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008; 105: 15112-15117 doi:10.1073/pnas.0807027105
• 7 Rahi JS, Cable N. British Childhood Visual Impairment Study Group. Severe visual impairment and blindness in children in the UK. Lancet 2003; 362: 1359-1365 doi:10.1016/S0140-6736(03)14631-4